Navigation Links
Yongye Biotechnology International Retains CCG Investor Relations
Date:8/8/2008

BEIJING, Aug. 8 /Xinhua-PRNewswire-FirstCall/ -- Yongye Biotechnology International, Inc. (OTC Bulletin Board: YGYB) ("Yongye" or the "Company"), a leading developer, producer and distributor of nutrients for plants and animals in the People's Republic of China, today announced that it has retained CCG Investor Relations to assist in the design and execution of its investor relations program.

Yongye is engaged in the development, distribution and sales of fulvic acid based liquid and powder nutrients for plants and animals. Yongye currently markets and sells its nutrients for plants in ten provinces and its nutrients for animals in four provinces. The Company sold 106,000 units (approximately 1,100 metric tons) of nutrients for plants and 13,800 units (approximately 4 metric tons) of nutrients for animals in 2007. Nutrients for plants contributed 87%, and nutrients for animals contributed 13%, of the Company's $13.1 million total revenue in 2007. In the first quarter of 2008, the Company sold 75,500 units of nutrients for plants (approximately 756 metric tons) and 47,035 units of nutrients for animals (approximately 14 metric tons), which contributed 83% and 17%, respectively, of the Company's $9.5 million total revenue.

"Our proprietary technology for fulvic acid extraction produces some of the purest and most bioactive fulvic acid in China. We combine this fulvic acid base with other ingredients using our proprietary formulae to create some of the most effective nutrients for plants and animals available in China. We plan to increase distribution and sales within our existing markets in the third and fourth quarters of 2008, and help our customers consistently achieve reliable results through use of our high quality products," said Mr. Zishen Wu, Chairman and CEO of Yongye Biotechnology International, Inc. "Along with expanding our operations, we look forward to working with CCG to improve our visibility in the investment community and with the financial media."

"China has a total of 155 million hectares of arable farmland. China's large population means that its arable farmland must feed an average of 10 people per hectare compared to a worldwide average of 4.4 people per hectare. China's farmland is currently being used at close to capacity levels just to meet domestic demand. A combination of limited arable land and a large and growing population has created a significant need to increase output per hectare in China," commented Crocker Coulson, President of CCG Investor Relations. "We look forward to helping Yongye achieve a strong dialogue with US investors."

About Yongye Biotechnology International, Inc.

Yongye Biotechnology International, Inc., headquartered in Beijing, is engaged in the development, distribution and sales of fulvic acid based nutrients for plants and animals. The Company's patent pending processes and proprietary formulas allow it to create products which increase crop yields and improve the health of livestock. Its sole operating subsidiary, Yongye Nongfeng Biotechnology Company, Ltd., is located in Inner Mongolia. The Company sells its products through distributors and directly to farmers located in ten provinces throughout China.

Forward-looking Statements

Certain statements set forth in this press release constitute "Forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. All such forward-looking statements involve risks and uncertainties, including, but not limited to: statements regarding the Company's products; marketing and sales; patents and regulatory approvals; the effect of competition and proprietary rights of third parties; the need for and availability of additional financing and access to capital; the seeking of joint development, licensing or distribution and collaboration and marketing arrangements with other companies. There can be no assurance that such forward-looking statements will prove to be accurate and Yongye undertakes no obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements.

For more information, please contact:

Yongye Biotechnology International, Inc.

Mr. Larry Gilmore-VP of Corporate Strategy

Tel: +1-818-390-1272

Email: larry.gilmore@gmail.com

CCG Investor Relations, Inc.

Mr. Crocker Coulson, President

Tel: +1-646-213-1915 (New York)

Email: crocker.coulson@ccgir.com

Web: http://www.ccgir.com


'/>"/>
SOURCE Yongye Biotechnology International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Yongye Biotechnology International, Inc. Appoints New Independent Auditor
2. Yongye Biotechnology Completes Reverse Merger and Completes $10.0 Million Private Financing
3. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
4. New Book on the Business of Biotechnology
5. InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th
6. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
7. Athera Biotechnology Founder Johan Frostegard and His Colleagues Win NACB Distinguished Abstract Award at AACC 2008
8. Pennsylvania Governor Rendell Says State Number 1 in New Biotechnology Study
9. WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
10. Genetic Engineering & Biotechnology News reports on novel hit-to-lead drug discovery
11. Dietitian Mary Lee Chin Comments on Proven Value and Safety of Food Biotechnology in New Online Video
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... pharmaceutical and biotechnology industries to improve patient outcomes and quality of life, will ... analytical testing are being attributed to new regulatory requirements for all new drug ...
(Date:10/11/2017)... ... ... is a basic first aid supply for any work environment, but most personal eye wash ... if a dangerous substance enters both eyes? It’s one less decision, and likely quicker response ... piece. , “Whether its dirt and debris, or an acid or alkali, getting anything in ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/10/2017)... ... 10, 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, ... The bold new look is part of a transformation to increase awareness, appeal ... growth period. , It will also expand its service offering from its signature gourmet ...
Breaking Biology Technology:
(Date:10/4/2017)... Solutions, a global clinical research organization (CRO), announces the launch of ... 4, 2017. Shadow is designed to assist medical writers and biometrics ... the European Medicines Agency (EMA) in meeting the requirements for de-identifying ... ... ...
(Date:7/20/2017)... Delta (NYSE: DAL ) customers now can use ... Reagan Washington National Airport (DCA). ... Delta launches biometrics to board aircraft at Reagan Washington ... Delta,s biometric boarding pass experience that ... integrated into the boarding process to allow eligible Delta SkyMiles Members who ...
(Date:6/14/2017)... -- IBM (NYSE: IBM ) is introducing several innovative partner ... developing collaboration between startups and global businesses, taking place in ... event, nine startups will showcase the solutions they have built ... France is one of ... 30 percent increase in the number of startups created between ...
Breaking Biology News(10 mins):